The Foundation for the National Institute of Health Seeks Public Comment - - BioPharm International

ADVERTISEMENT

The Foundation for the National Institute of Health Seeks Public Comment



The Observational Medical Outcomes Partnership (OMOP), a public–private partnership managed by the nonprofit Foundation for the National Institutes of Health and chaired by FDA, conducts methodological research on the use of observational healthcare data in studying the effects of medical products. The OMOP executive board is seeking public feedback on the priorities, infrastructure tasks, and research tasks it has proposed for 2013–2016.  Comments are being collected via the OMOP website through Sept. 15, 2012.

“Receiving public feedback regarding OMOP’s work is vital to our success,” said OMOP executive board member, Ronald Krall, MD, in an Aug. 27, 2012 press release. “We want to make sure we hear every idea about how to use healthcare data to improve the safety and effectiveness of medical products.”

OMOP was formed in 2008, and the group’s research since then has affirmed its belief that the science of observational research requires an empirical and reproducible approach to methodology and systematic application.  OMOP’s research has generated empirical evidence about the ability of observational analysis methods to identify true risks of medical products and discriminate from false findings.  Experiments were designed to understand how an estimated effect from an observational study relates to the true relationship between medical product exposure and adverse events.

Proposed priorities for upcoming research, described in the OMOP Call for Comments, include creating a foundation for the common representation of healthcare data, developing empirical evidence to support study of the association between medical interventions and adverse outcomes, developing empirical evidence to aid detection of unsuspected associations between medical events and interventions, and creating a framework for evidence-based decision making.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines

Click here